CA2330623A1 - 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie - Google Patents

11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie Download PDF

Info

Publication number
CA2330623A1
CA2330623A1 CA002330623A CA2330623A CA2330623A1 CA 2330623 A1 CA2330623 A1 CA 2330623A1 CA 002330623 A CA002330623 A CA 002330623A CA 2330623 A CA2330623 A CA 2330623A CA 2330623 A1 CA2330623 A1 CA 2330623A1
Authority
CA
Canada
Prior art keywords
benzo
naphtho
carbon atoms
thiophen
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330623A
Other languages
English (en)
Inventor
Zenan Li
Jay Edward Wrobel
Arlene Joan Dietrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2330623A1 publication Critical patent/CA2330623A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) de structure, dans laquelle A est un hydrogène, un halogène ou un OH; B et D sont chacun, de manière indépendante, un hydrogène, un halogène, un CN, un alkyle contenant de 1 à 6 atomes de carbone, un aryle, un aralkyle contenant de 6 à 12 atomes de carbone, un nitro, un amino ou un OR; R est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un -COR?1¿, un -CH¿2?CO¿2?R?1¿, un -CH(R?1a¿)CO¿2?R?1¿, ou un -SO¿2?R?1¿; R?1¿ et R?1a¿ sont chacun, de manière indépendante, un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aralkyle contenant de 6 à 12 atomes de carbone, ou un aryle; E est un S, un SO, un SO¿2?, ou un O; X est un hydrogène, un halogène, un alkyle contenant de 1 à 6 atomes de carbone, un CN, un perfluoroalkyle contenant de 1 à 6 atomes de carbone, un alkoxy contenant de 1 à 6 atomes de carbone, un aryloxy, un arylalkoxy contenant de 6 à 12 atomes de carbone, un nitro, un amino, un alkylsulfanyle contenant de 1 à 6 atomes de carbone, un arylsulfanyle, un pyridylsulfanyle, un 2-N,N-diméthylaminoéthylsulfanyle, ou un -OCH¿2?CO¿2?R?1b¿; R?1b¿ est un hydrogène ou un alkyle contenant de 1 à 6 atomes de carbone ; Y et Z sont chacun, de manière indépendante, un hydrogène ou un OR¿2?; R?2¿ est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aralkyle contenant de 6 à 12 atomes de carbone, ou un -CH2CO¿2?R?3¿; R?3¿ est un hydrogène ou un alkyle contenant de 1 à 6 atomes de carbone; C est un hydrogène, un halogène ou un OR?4¿; R?4¿ est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un -CH(R?5¿)W, un -C(CH¿3?)¿2?CO¿2?R?6¿, un 5-thiazolidine-2,4-dione, un -CH(R?7¿)CH¿2?CO¿2?R?6¿, un -COR?6¿, un -PO¿3?(R?6¿)¿2?, ou un -SO¿2?R?6¿; R?5¿ est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aralkyle, un aryle, un -CH¿2?(1H-imidazole-4-yl), un -CH¿2?(3-1H-indolyl), un -CH¿2?CH¿2?(1,3-dioxo-1,3-dihydro-isoindol-2-yl), un -CH¿2?CH¿2?(1-oxo-1,3-dihydro-isoindol-2-yl), un -CH¿2?(3-pyridyl), ou un -CH¿2?CO¿2?H; W est un -CO¿2?R?6¿, un -CONH¿2?, un -CONHOH, un CN, un -CONH(CH¿2?)¿2?CN, un 5-tétrazole, un -PO¿3?(R?6¿)¿2?, un -CH¿2?OH, un -CH¿2?Br ou un -CONR?6¿CHR?7¿CO¿2?R?8¿; R?6¿ est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aryle ou un aralkyle; R?7¿ est est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aryle ou un aralkyle; R?8¿ est un hydrogène, un alkyle contenant de 1 à 6 atomes de carbone, un aryle ou un aralkyle. Ces composés ou un de leurs sels acceptables sur le plan pharmaceutique, sont utiles dans le traitement des troubles métaboliques qui se rapportent à la résistance insulinique ou à l'hyperglycémie.
CA002330623A 1998-05-12 1999-05-10 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie Abandoned CA2330623A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7659298A 1998-05-12 1998-05-12
US09/076,592 1998-05-12
PCT/US1999/010185 WO1999058521A1 (fr) 1998-05-12 1999-05-10 11-ARYL-BENZO[B]NAPHTO[2,3-D]FURANES ET 11-ARYL-BENZO[b]NAPHTO[2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE

Publications (1)

Publication Number Publication Date
CA2330623A1 true CA2330623A1 (fr) 1999-11-18

Family

ID=22133016

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330623A Abandoned CA2330623A1 (fr) 1998-05-12 1999-05-10 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie

Country Status (6)

Country Link
EP (1) EP1077970A1 (fr)
JP (1) JP2002514638A (fr)
CN (1) CN1308627A (fr)
AU (1) AU3979199A (fr)
CA (1) CA2330623A1 (fr)
WO (1) WO1999058521A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281238B1 (en) * 1998-05-12 2001-08-28 American Home Products Corporation 4-aryl-1-oxa-9-thia-cylopenta[B]fluorenes
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
JP2004521124A (ja) 2001-02-09 2004-07-15 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
DE10140148B4 (de) 2001-08-16 2012-07-19 Merck Patent Gmbh Fluorierte Polycyclen und ihre Verwendung in Flüssigkristallmischungen und in Flüssigkristalldisplays
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
CN101172983A (zh) * 2002-03-20 2008-05-07 麦它波莱克斯股份有限公司 取代的苯乙酸
EP1554262B1 (fr) 2002-10-23 2007-12-05 Glenmark Pharmaceuticals Limited Nouveaux composes tricycliques utiles pour traiter les troubles inflammatoires et allergiques, procede de preparation de ces composes et compositions pharmaceutiques les contenant
EA010634B1 (ru) 2003-04-11 2008-10-30 Гленмарк Фармасьютикалс С.А. Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
US7718377B2 (en) 2003-05-29 2010-05-18 Kyoto Pharmaceutical Industries, Ltd. Insulin resistance curative and method of screening the same
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005035551A2 (fr) 2003-10-08 2005-04-21 Incyte Corporation Inhibiteurs de proteines se liant a des molecules phosphorylees
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006011024A2 (fr) * 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. Nouveaux composes tricycliques utilises dans le traitement de troubles inflammatoires et allergiques, procede de preparation associe, et compositions pharmaceutiques les contenant
CN101124229B (zh) 2004-12-17 2012-07-18 格兰马克药品股份有限公司 用于治疗炎性和过敏性障碍的新杂环化合物
EP1831227B1 (fr) 2004-12-17 2013-06-19 Glenmark Pharmaceuticals S.A. Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CA2905435A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CN105592846A (zh) 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750426B1 (fr) * 1996-06-28 1998-08-07 Cird Galderma Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique

Also Published As

Publication number Publication date
EP1077970A1 (fr) 2001-02-28
JP2002514638A (ja) 2002-05-21
WO1999058521A1 (fr) 1999-11-18
CN1308627A (zh) 2001-08-15
AU3979199A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
CA2330623A1 (fr) 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie
AU756337B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
US6444670B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077967B1 (fr) Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6369072B2 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999058519A1 (fr) Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6110962A (en) 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
WO1999058522A1 (fr) Derives de naphto[2,3-b]heteroar-4-yle
US6248764B1 (en) Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6121271A (en) Naphtho[2,3-B]heteroar-4-yl derivatives
US6001867A (en) 1-aryl-dibenzothiophenes
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
MXPA00011089A (en) 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
MXPA00011091A (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
CZ20004182A3 (cs) Deriváty benzothiofenu, benzofuranu a indolu
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia

Legal Events

Date Code Title Description
FZDE Dead